During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

The combined assessment of analysts suggests that 'Sales- Oncology- Alliance revenue- Lenvima' will likely reach $275.08 million. The estimate indicates a year-over-year change of +5.8%.

Please note that Merck markets Lynparza in partnership with AstraZeneca AZN. Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by ...